Á¦17ȸ ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ Æó¾Ï ½ÉÆ÷Áö¾ö : 2022-04-08±³À°ÀÏÀÚ : 2022-04-08
±³À°Àå¼Ò : °æÁÖȹéÄÁº¥¼Ç¼¾ÅÍ(HICO)
±³À°ÁÖÁ¦ :
Á¦17ȸ ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ Æó¾Ï ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ
´ã´çÀÚ : ±è¹Ì¼±
¿¬¶ôó : 02-575-3825
À̸ÞÀÏ :
katrd@hanmail.net ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
°æ»óºÏµµ±³À°½Ã°£ : 4 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í »çÀüµî·Ï : Àü¹®ÀÇ, ÀϹÝÀÇ 30,000¿ø / Àü°øÀÇ, ±âŸ 20,000¿ø ÇöÀåµî·Ï : Àü¹®ÀÇ, ÀϹÝÀÇ 40,000 / Àü°øÀÇ, ±âŸ 30,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-08 3F 12:40~13:40 ¡°Antifibrotic Therapy in Fibrosing ILD : Lessons from 10 Years of Experience¡± ¼ÛÁø¿ì(¿ï»êÀÇ´ë)
±³À°½Ã°£ 04-08 3F 14:10~14:40 1. Impact of Exercise and Nutrition on the Immune System and Outcomes in NSCLC ¹ÚÁøÇÑ(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 04-08 3F 14:40~15:10 2. Lung Cancer Treatment in COVID-19 Era °´ÙÇö(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 04-08 3F 15:10~15:40 3. The Problematic Cases of Pathologic Diagnosis with Suspected Lung Cancer ¾öÁß¼·(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 04-08 3F 16:00~16:30 4. Newly Approved Targeted Agents ÀÌ»óÈÆ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-08 3F 16:30~17:00 5. Advanced Adjuvant Therapy in NSCLC ÀÓÁ¤¿í(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04-08 3F 17:00~17:30 6. Not Common But, Essential Adverse Events in Patients Being Treated with ICIs À̽ÂÇö(°æÈñÀÇ´ë)
±³À°½Ã°£ 04-08 3F 17:30~18:10 ¡°Optimal therapy for treatment in all severity of Asthma¡° ±èÁø¿ì(°¡Å縯ÀÇ´ë)